These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 23234477)

  • 1. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
    Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
    DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylases.
    Huang Y; Shaw PG; Davidson NE
    Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of tumor cells by targeting histone deacetylases.
    Perego P; Zuco V; Gatti L; Zunino F
    Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
    Botrugno OA; Santoro F; Minucci S
    Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDACs as an emerging target in endocrine tumors: a comprehensive review.
    Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.